Abstract:Abstract Enhancer of zeste homolog 2 (EZH2) is the histone lysine N-methyltransferase component of the Polycomb repressive complex 2 (PRC2), which, in conjunction with embryonic ectoderm development (EED) and suppressor of zeste 12 homolog(SUZ12), regulates cell lineage determination and homeostasis. Enzymatic hyperactivity of EZH2 has been linked to aberrant repression of tumor suppressor genes in diverse cancers. Here, we report the development of stabilized a-helix of EZH2 (SAH-EZH2) peptides that selectively inhibit H3 Lys27 trimethylation by dose-responsively disrupting the EZH2-EED complex and reducing EZH2 protein levels, a mechanism distinct from that reported for small-molecule EZH2 inhibitors targeting the enzyme catalytic domain. The essential α-helical domain of EZH2 (residues 40-68) that engages EED established the basis for designing hydrocarbon-stapled derivatives to disrupt the specific protein interaction. Non-natural amino acids with olefinic side chains were substituted at (i, i + 4) positions within the EZH2 α-helical sequence, followed by ruthenium-catalyzed olefin metathesis, to yield SAH-EZH2 peptides. Our lead, cell-permeable analog effectively targeted EED in situ, dissociated the EZH2-EED complex and impaired the function of PRC2, as reflected by reduction of the H3K27me3 and EZH2 protein levels, and increased expression of PRC2-regulated cell differentiation marker genes. In response to SAH-EZH2 treatment, murine MLL-AF9 leukemia cells, which are PRC2-dependent, manifested growth arrest and monocyte-macrophage differentiation, in accordance with the phenotypic consequences of shRNA-mediated reduction of EZH2 (or EED) or genetic ablation of Ezh2 (or Eed). In evaluating SAH-EZH2 activity alongside the small-molecule EZH2 inhibitor GSK126 in a series of B-cell lymphoma lines, we observed sequence-specific antiproliferative responses, transcriptional modulation, cellular specificity and a distinct mechanism of action for SAH-EZH2. Citation Information: Mol Cancer Ther 2013;12(11 Suppl):B254. Citation Format: Woojin Kim, Gregory H. Bird, Tobias Neff, Guoji Guo, Marc A. Kerenyi, Loren D. Walensky, Stuart H. Orkin. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr B254.

EEDi-5285: an Exceptionally Potent, Efficacious, and Orally Active Small-Molecule Inhibitor of Embryonic Ectoderm Development.

Discovery of EEDi-5273 As an Exceptionally Potent and Orally Efficacious EED Inhibitor Capable of Achieving Complete and Persistent Tumor Regression.

Discovery And Molecular Basis Of A Diverse Set Of Polycomb Repressive Complex 2 Inhibitors Recognition By Eed

The EED Protein–protein Interaction Inhibitor A-395 Inactivates the PRC2 Complex

Docking and 3D-QSAR Studies on the Imidazo[1,5-c]pyrimidine Derivative as EED Inhibitors

Structure-Guided Development of Small-Molecule PRC2 Inhibitors Targeting EZH2-EED Interaction.

Recent strategies targeting Embryonic Ectoderm Development (EED) for cancer therapy: Allosteric inhibitors, PPI inhibitors, and PROTACs

Identification of potent pan-ephrin receptor kinase inhibitors using DNA-encoded chemistry technology

Abstract B254: Targeted Disruption of the EZH2-EED Complex Inhibits EZH2-dependent Cancer.

Identification of a cytisine-based EED-EZH2 protein-protein interaction inhibitor preventing metastasis in triple-negative breast cancer cells

Targeting EED as a key PRC2 complex mediator toward novel epigenetic therapeutics

Development of a high-throughput fluorescence polarization assay for the discovery of EZH2-EED interaction inhibitors

Structure-Based Design of the Indole-Substituted Triazolopyrimidines as New EED-H3K27me3 Inhibitors for the Treatment of Lymphoma

Binding Modes of Small-Molecule Inhibitors to the EED Pocket of PRC2

Development of Potent NEDD8-Activating Enzyme Inhibitors Bearing a Pyrimidotriazole Scaffold.

Discovery of the First Potent and Selective Inhibitor of Centromere-Associated Protein E: GSK923295

Abstract LB-A09: EED Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex

Astemizole Arrests the Proliferation of Cancer Cells by Disrupting the EZH2-EED Interaction of Polycomb Repressive Complex 2

Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer

Potent and Selective Inhibitor of the Mitotic Kinesin Cenp-E (gsk923295a), Demonstrates A Novel Mechanism of Inhibiting Tumor Cell Proliferation and Shows Activity Against A Broad Panel of Human Tumor Cell Lines in Vitro

Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer.